---
layout: default
title: Lixisenatide
parent: 僅模型預測 (L5)
nav_order: 213
evidence_level: L5
indication_count: 0
---

# Lixisenatide
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Lixisenatide: Repurposing Evaluation Report (Prediction Data Pending)

---

## One-Sentence Summary

Lixisenatide (DB09265) is a GLP-1 receptor agonist most commonly indicated for the management of type 2 diabetes mellitus, used in combination with basal insulin or oral antidiabetics.
This evidence pack **does not contain TxGNN model prediction results** — the `predicted_indications` array is empty — so no new repurposing indication can be formally evaluated at this time.
Malaysia NPRA records confirm the drug is currently marketed under 2 registrations, but licence details and safety data remain unavailable in this version of the pack.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Type 2 Diabetes Mellitus (GLP-1 receptor agonist class) |
| Predicted New Indication | — (no TxGNN prediction data present) |
| TxGNN Prediction Score | — |
| Evidence Level | N/A — prediction output absent |
| Malaysia Market Status | ✓ Marketed |
| Number of Registrations | 2 |
| Recommended Decision | **Hold** |

---

## Why Is This Prediction Reasonable?

This section cannot be completed as no predicted indication is present in the `predicted_indications` field of this evidence pack.

For background context: lixisenatide is a selective GLP-1 receptor agonist that acts by enhancing glucose-dependent insulin secretion, suppressing postprandial glucagon release, and slowing gastric emptying. The GLP-1 signalling pathway has attracted growing research interest beyond glycaemic control — published studies have explored its role in cardiovascular protection, obesity, non-alcoholic steatohepatitis (NASH), and neurodegenerative diseases such as Parkinson's and Alzheimer's disease. These mechanistic links suggest plausible repurposing directions, but they must be anchored to an actual TxGNN prediction score and supporting evidence before formal evaluation can proceed.

Additionally, detailed MOA data was flagged as a data gap (DG002); retrieval from the DrugBank API is recommended to supplement this analysis.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

> *Reason: No predicted indication is available in this evidence pack. Without a target disease, no clinical trial query was performed.*

---

## Literature Evidence

Currently no related literature available.

> *Reason: No predicted indication is available in this evidence pack. Without a target disease, no PubMed query was performed.*

---

## Malaysia Market Information

Two product licences are registered under Malaysia's NPRA for lixisenatide. However, the individual licence details — including product name, dosage form, manufacturer, and approved indication text — were not returned in this evidence pack (all fields are blank strings).

| Authorization Number | Product Name | Dosage Form | Approved Indication |
|----------------------|--------------|-------------|---------------------|
| — | — | — | Details not available in this evidence pack |
| — | — | — | Details not available in this evidence pack |

Please verify directly via the **NPRA e-Search portal**: https://www.npra.gov.my/index.php/en/industry/registration/product-registration/check-product-registration-status.html

---

## Safety Considerations

Please refer to the package insert for safety information.

> All safety fields in this evidence pack are data gaps: key warnings, contraindications, and drug-drug interaction records were not retrieved. This was flagged as a **Blocking** issue (DG001) — the NPRA/TFDA package insert PDF should be downloaded and parsed before any safety-gated evaluation can proceed.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This evidence pack is structurally incomplete — no TxGNN prediction results are present, licence details are blank, and all safety data is missing. A meaningful repurposing evaluation requires at minimum a target indication with a model confidence score and basic safety clearance.

**To proceed, the following is needed:**

- **Re-run TxGNN model** for lixisenatide (DB09265) to populate `predicted_indications` with candidate diseases and confidence scores
- **Retrieve MOA data** from the DrugBank API (DG002 — High severity) to support mechanism-of-action analysis
- **Parse the NPRA/manufacturer package insert PDF** to extract approved indications, key warnings, and contraindications (DG001 — Blocking)
- **Populate licence details** (product name, dosage form, approved indication text) from NPRA records for the 2 registered products
- Once a predicted indication is identified, re-collect clinical trial (ClinicalTrials.gov / ICTRP) and PubMed literature evidence to assign a proper evidence level (L1–L5)
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

